Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
出版年份 2015 全文链接
标题
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
作者
关键词
-
出版物
Expert Opinion on Drug Discovery
Volume 10, Issue 8, Pages 925-935
出版商
Informa Healthcare
发表日期
2015-06-03
DOI
10.1517/17460441.2015.1045411
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
- (2014) B Escudier et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- (2014) Jose A. Karam et al. EUROPEAN UROLOGY
- Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
- (2013) Matteo Santoni et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
- (2013) T. Ueda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib dose titration: what's the limiting factor?
- (2013) Sebastiano Buti et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
- (2012) L P Martin et al. BRITISH JOURNAL OF CANCER
- Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
- (2012) M F Kozloff et al. BRITISH JOURNAL OF CANCER
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
- (2012) Ronald M. Bukowski Frontiers in Oncology
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers
- (2011) Y. Chen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
- (2011) Jean-Philippe Spano et al. INVESTIGATIONAL NEW DRUGS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
- (2010) Joaquim Bellmunt et al. Clinical & Translational Oncology
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
- (2010) Michael A. Tortorici et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
- (2009) S. Sharma et al. ANNALS OF ONCOLOGY
- Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
- (2009) Y. K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- (2009) Hassane Izzedine et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
- (2009) Ronan J. Kelly et al. Targeted Oncology
- Myeloid-derived suppressor cells: A novel therapeutic target
- (2009) Jennifer S. Ko et al. Current Oncology Reports
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma
- (2008) Ingrid Alexandre et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started